TY - JOUR AU - Csatordai, Márta AU - Benkő, Ria AU - Matuz, Mária AU - Engi, Zsófia AU - Csupor, Dezső AU - Lengyel, Csaba Attila AU - Doró, Péter TI - Trends and regional differences in antidiabetic medication use: a nationwide retrospective observational study JF - DIABETOLOGY AND METABOLIC SYNDROME J2 - DIABETOL METAB SYNDR VL - 16 PY - 2024 IS - 1 PG - 10 SN - 1758-5996 DO - 10.1186/s13098-024-01334-8 UR - https://m2.mtmt.hu/api/publication/34824725 ID - 34824725 LA - English DB - MTMT ER - TY - JOUR AU - Bahar, Muhammad Akbar AU - Kusuma, Ikhwan Yuda AU - Visnyovszki, Ádám AU - Matuz, Mária AU - Benkő, Ria AU - Ferenci, Tamás AU - Szabó, Bálint Gergely AU - Hajdú, Edit AU - Pető, Zoltán AU - Csupor, Dezső TI - Favipiravir does not improve viral clearance in mild to moderate COVID-19 – a systematic review and meta-analysis of randomized controlled trials JF - HELIYON J2 - HELIYON VL - 10 PY - 2024 IS - 9 PG - 15 SN - 2405-8440 DO - 10.1016/j.heliyon.2024.e29808 UR - https://m2.mtmt.hu/api/publication/34796471 ID - 34796471 LA - English DB - MTMT ER - TY - JOUR AU - Dewi, Ni Made Amelia Ratnata AU - Benkő, Ria AU - Engi, Zsófia AU - Csupor, Dezső AU - Viola, Réka AU - Csatordai, Márta AU - Matuz, Mária TI - Pain management: opioid use in hospitals JF - EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE J2 - EUR J HOSP PHARM SCI PRACT VL - 31 PY - 2024 IS - S1 SP - A242 EP - A243 PG - 1 SN - 2047-9956 DO - 10.1136/ejhpharm-2024-eahp.501 UR - https://m2.mtmt.hu/api/publication/34791311 ID - 34791311 LA - English DB - MTMT ER - TY - JOUR AU - Gulyás, Eszter AU - Horváth, István László AU - Engh, Marie Anne AU - Bunduc, Stefania AU - Dembrovszky, Fanni AU - Fehérvári, Péter AU - Bánvölgyi, András AU - Csupor, Dezső AU - Hegyi, Péter AU - Karvaly, Gellért Balázs TI - Assessment of the practical impact of adjusting beta-lactam dosages based on therapeutic drug monitoring in critically ill adult patients: a systematic review and meta-analysis of randomized clinical trials and observational studies JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 14 PY - 2024 IS - 1 PG - 13 SN - 2045-2322 DO - 10.1038/s41598-024-58200-w UR - https://m2.mtmt.hu/api/publication/34776969 ID - 34776969 N1 - Centre for Translational Medicine, Semmelweis University, Budapest, Hungary University Pharmacy Department of Pharmacy Administration, Semmelweis University, Budapest, Hungary Department of Laboratory Medicine, Semmelweis University, 4 Nagyvarad ter, Budapest, 1089, Hungary Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary Carol Davila University of Medicine and Pharmacy, Bucharest, Romania Fundeni Clinical Institute, Bucharest, Romania First Department of Medicine, University of Pécs, Pécs, Hungary János Szentágothai Research Center, University of Pécs, Pécs, Hungary Department of Biostatistics, University of Veterinary Medicine, Budapest, Hungary Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary Department of Clinical Pharmacy, University of Szeged, Szeged, Hungary Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, Budapest, Hungary Export Date: 12 April 2024 Correspondence Address: Karvaly, G.B.; Centre for Translational Medicine, Hungary; email: karvaly.gellert.balazs@semmelweis.hu LA - English DB - MTMT ER - TY - JOUR AU - Bérczi, Bálint AU - Borbásné Farkas, Kornélia AU - Hegyi, Péter AU - Tóth, Barbara AU - Csupor, Dezső AU - Németh, Balázs AU - Lukács, Anita AU - Czumbel, László Márk AU - Kerémi, Beáta AU - Kiss, István AU - Szabó, Andrea AU - Varga, Gábor AU - Gerber, Gábor AU - Gyöngyi, Zoltán TI - Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis JF - JOURNAL OF CLINICAL MEDICINE J2 - J CLIN MED VL - 13 PY - 2024 IS - 6 PG - 20 SN - 2077-0383 DO - 10.3390/jcm13061818 UR - https://m2.mtmt.hu/api/publication/34760472 ID - 34760472 N1 - Journal Article; Review AB - Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels initiate changes in lipid profiles. Aromatase inhibitors (AI) are used to prevent the progression of cancer; however, a further reduction in estrogen levels may have detrimental effects on lipid levels, which was our working hypothesis. Methods: Our meta-analysis was conducted on the lipid profiles of postmenopausal breast cancer patients at baseline and at different treatment time points. Results: We identified 15 studies, including 1708 patients. Studies using anastrozole (ANA), exemestane (EXE), letrozole (LET), and tamoxifen (TMX) were involved. Subgroup analyses revealed that 3- and 12-month administrations of LET and EXE lead to negative changes in lipid profiles that tend to alter the lipid profile undesirably, unlike ANA and TMX. Conclusions: Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia. LA - English DB - MTMT ER - TY - JOUR AU - Tóth, Barbara AU - Horváth, Attila AU - Jójártné Laczkovich, Orsolya AU - Biró, Dalma AU - Matuz, Mária AU - Csupor, Dezső TI - Storage Conditions Influence the Quality of Ginger – A Stability Study Inspired by Clinical Trials JF - PLANTA MEDICA: NATURAL PRODUCTS AND MEDICINAL PLANT RESEARCH J2 - PLANTA MED PY - 2024 SN - 0032-0943 DO - 10.1055/a-2283-8147 UR - https://m2.mtmt.hu/api/publication/34728728 ID - 34728728 N1 - Funding Agency and Grant Number: Ministry of Innovation and Technology of Hungary [TKP2021-EGA, TKP2021-EGA-32]; Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund Funding text: This work was supported by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-EGA funding scheme; project No. TKP2021-EGA-32 has been implemented with the support provided. AB - Ginger has traditionally been used to treat and prevent nausea and vomiting; however, the results of clinical trials are ambiguous. The efficacy of ginger is attributed to gingerols and their metabolites, shogaols. Since these compounds have different pharmacological profiles, the clinical efficacy of ginger products is largely dependent on their chemical composition. The goal of our study was to examine the stability of ginger determining the 6-gingerol contents in order to assess the effects of different storage conditions. We have performed a 6-month stability test with dry ginger rhizome samples stored in a constant climate chamber in three different storage containers (uncovered glass container, glass container sealed with rubber stopper, plastic container). 6-gingerol contents were measured by HPLC method. The concentration of 6-gingerol decreased in all samples. In the sealed glass container, the decrease of 6-gingerol content was significantly lower than in the unsealed glass container and in the plastic container. These results demonstrate that storage conditions have a significant impact on the quality of ginger, which may also affect efficacy. LA - English DB - MTMT ER - TY - JOUR AU - Galajda, Noémi Ágnes AU - Meznerics, Fanni Adél AU - Mátrai, P. AU - Fehérvári, Péter AU - Lengyel, Anna Sára AU - Kolonics, Mária Veronika AU - Sipos, Z. AU - Kemény, Lajos Vince AU - Csupor, Dezső AU - Hegyi, Péter AU - Bánvölgyi, András AU - Holló, Péter TI - Reducing cardiovascular risk in immune‐mediated inflammatory diseases: Tumour necrosis factor inhibitors compared to conventional therapies—A systematic review and meta‐analysis JF - JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY J2 - J EUR ACAD DERMATOL PY - 2024 SN - 0926-9959 DO - 10.1111/jdv.19900 UR - https://m2.mtmt.hu/api/publication/34723194 ID - 34723194 N1 - Correction added on 4 April 2024, after first online publication: P. Mátrai's affiliation has been corrected.P. Holló and A. Bánvölgyi share the last authorship AB - Immune‐mediated inflammatory disease (IMID) patients including psoriasis, inflammatory arthritides and bowel diseases have a higher risk of developing cardiovascular (CV) diseases compared to the general population. The increased CV risk may be promoted by tumour necrosis factor (TNF)‐α‐mediated immunological processes, which are present both in the pathomechanism of IMIDs and atherosclerosis. Our objective was to comprehensively investigate the effect of TNF inhibitors (TNFi) on CV risk compared with conventional therapies in IMIDs. The systematic literature search was conducted in three databases (MEDLINE, EMBASE, Cochrane Library) on 14 November 2022. Randomized controlled trials, cohort and case–control studies were eligible for inclusion. Outcomes consisted of the incidence of CV events, with major adverse cardiovascular events (MACE) as a main endpoint. A random‐effects meta‐analysis was performed by pooling fully adjusted multivariate hazard ratios (HR) and incidence rate ratios (IRR) with a 95% confidence interval (CI) comparing TNFis with conventional systemic non‐biologicals (CSNBs). Of a total of 8724 search results, 56 studies were included overall, of which 29 articles were eligible for the meta‐analysis, and 27 were involved in the systematic review. Including all IMIDs, the TNFi group showed a significantly reduced risk of MACE compared with the CSNB group (HR = 0.74, 95% confidence interval (CI) 0.58–0.95, p = 0.025; IRR = 0.77, 95% CI 0.67–0.88, p < 0.001). Subgroup analysis of Pso, PsA patients by pooling IRRs also confirmed the significantly decreased risk of MACE in TNFi‐treated patients compared with CSNB groups (IRR = 0.79, 95% CI 0.64–0.98). The observational nature of most included studies leading to high heterogeneity represents a limitation. Based on the results, TNFis may reduce the risk of CV events compared to CSNBs. Therefore, earlier use of TNFis compared to conventional systemic agents in the therapeutic sequence may benefit CV risk in IMID patients. LA - English DB - MTMT ER - TY - JOUR AU - Kusuma, Ikhwan Yuda AU - Bahar, Muhammad Akbar AU - Nuari, Doni Anshar AU - Prabandari, Rani AU - Soeharto, Soeharto AU - Csupor, Dezső AU - Benkő, Ria AU - Matuz, Mária TI - Antibiotic knowledge assessment questionnaire in undergraduate pharmacy students: A Rasch analysis of validity evidence JF - PHARMACY EDUCATION J2 - PHARM EDUC VL - 24 PY - 2024 IS - 1 SP - 54 EP - 78 PG - 25 SN - 1560-2214 DO - 10.46542/pe.2024.241.5478 UR - https://m2.mtmt.hu/api/publication/34577678 ID - 34577678 N1 - Export Date: 28 February 2024; CODEN: PLACB AB - Background: Antibiotic knowledge is crucial for undergraduate pharmacy students who are future healthcare professionals. However, a valid and reliable instrument to assess their knowledge is scarce. This study aimed to develop and validate an Antibiotic Knowledge Assessment Questionnaire (AKAQ).Methods: The AKAQ had three domains and 29 items, encompassing general antibiotic knowledge, antibiotic resistance, and antibiotic stewardship. Rasch analysis was used to assess psychometric properties, including validity parameters (item and person fit and structural validity), reliability (person and item reliability, Cronbach’s Alpha value), item-person interaction, and item bias, using differential item functioning (DIF) based on tems.Results: This study included 500 undergraduate pharmacy students from 90 Indonesian universities. The validity of the questionnaire was demonstrated, except for one item. Person means infit and outfit for MNSQ were 1.02 and 0.95, whereas ZSTD were 0.11 and 0.08, respectively. Items means infit and outfit for MNSQ were 1.01 and 0.96, while ZSTD were 0.11 and -0.23. Item and person reliabilities were acceptable at 0.99 and 0.68. Cronbach’s alpha reliability was acceptable at 0.71. Two items were biased by term.Conclusion: The AKAQ is a valid, reliable, and standard instrument for assessing the antibiotic knowledge levels of undergraduate pharmacy students. LA - English DB - MTMT ER - TY - JOUR AU - Kusuma, Ikhwan Yuda AU - Perdana, Muhammad Iqbal AU - Vágvölgyi, Csaba AU - Csupor, Dezső AU - Takó, Miklós TI - Exploring the Clinical Applications of Lemongrass Essential Oil: A Scoping Review JF - PHARMACEUTICALS J2 - PHARMACEUTICALS-BASE VL - 17 PY - 2024 IS - 2 PG - 13 SN - 1424-8247 DO - 10.3390/ph17020159 UR - https://m2.mtmt.hu/api/publication/34533361 ID - 34533361 N1 - Funding Agency and Grant Number: National Research, Development and Innovation Office Funding text: No Statement Available AB - Lemongrass is a medicinal plant that produces essential oil with a variety of therapeutic properties. Although lemongrass essential oil (LGEO) is promising in clinical applications, the existing knowledge on the efficacy and safety of LGEO remains limited. This scoping review aimed to identify, summarize, and synthesize existing literature related to the clinical applications of LGEO to provide an overview of its potential therapeutic benefits for patients. Three databases (PubMed, Web of Science, Scopus) were used following the PRISMA-ScR guidelines to find articles published between 1 January 2013, and 1 November 2022. A total of 671 records were identified and 8 articles were included in this scoping review. The majority of patients received oromucosal and topical treatment. The results of the studies suggest that LGEO might be a useful tool in the treatment of periodontitis, gingivitis and oral malodour, with similar efficacy to chlorhexidine (anti-gingivitis effect) and doxycycline (periodontitis). Additionally, LGEO has the potential for treating pityriasis versicolor and preventing skin aging and may have anti-dandruff effects. These findings not only underscore the diverse clinical potential of LGEO but also emphasize its comparable efficacy to established treatments. Further research is imperative to comprehensively evaluate LGEO’s effectiveness, safety, mechanisms of action, potential interactions with other medications, and its long-term tolerability across diverse populations. LA - English DB - MTMT ER - TY - JOUR AU - Ruzsa, Roxána AU - Benkő, Ria AU - Hambalek, Helga AU - Papfalvi, Erika Piroska AU - Csupor, Dezső AU - Nacsa, Róbert AU - Csatordai, Márta AU - Soós, Gyöngyvér AU - Hajdú, Edit AU - Matuz, Mária TI - Hospital Antibiotic Consumption before and during the COVID-19 Pandemic in Hungary JF - ANTIBIOTICS J2 - ANTIBIOTICS-BASEL VL - 13 PY - 2024 IS - 1 PG - 11 SN - 2079-6382 DO - 10.3390/antibiotics13010102 UR - https://m2.mtmt.hu/api/publication/34532941 ID - 34532941 N1 - Institute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, 6725, Hungary University Pharmacy Albert Szent-Györgyi Health Center, University of Szeged, Szeged, 6725, Hungary Department of Emergency Medicine, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, 6725, Hungary Institute of Translational Medicine, Medical School, University of Pécs, Pécs, 7624, Hungary Department of Internal Medicine Infectiology Unit, Albert Szent-Györgyi Health Centre, University of Szeged, Szeged, 6725, Hungary Export Date: 6 February 2024 Correspondence Address: Ruzsa, R.; Institute of Clinical Pharmacy, Hungary; email: roxana.ruzsa@med.u-szeged.hu Correspondence Address: Matuz, M.; Institute of Clinical Pharmacy, Hungary; email: matuz.maria@szte.hu AB - The aim of this study was to assess antibiotic use in the Hungarian hospital care sector during and before the pandemic. Aggregated systemic antibiotic (ATC: J01) utilisation data were obtained for the 2010–2021 period. Classifications and calculations were performed according to the WHO ATC/DDD index and expressed as DDD per 1000 inhabitants and per day (DID), DDD per 100 patient-days (DHPD) and DDD/discharge. A linear regression (trend analysis) was performed for the pre-COVID years (2010–2019) and a prediction interval was set up to assess whether the pandemic years’ observed utilisation fit in. Antibiotic utilisation was constant in DID before and during the pandemic (2019: 1.16; 2020: 1.21), while we observed a substantial increase in antibiotic use when expressed in DDD per 100 patient-days (2019: 23.3, 2020: 32.2) or DDD/discharge (2019: 1.83, 2020: 2.45). The observed utilisation level of penicillin combinations; first-, third- and fourth-generation cephalosporins; carbapenems; glycopeptides; nitroimidazoles and macrolides exceeded the predicted utilisation values in both pandemic years. Before the pandemic, co-amoxiclav headed the top list of antibiotic use, while during the pandemic, ceftriaxone became the most widely used antibiotic. Azithromycin moved up substantially on the top list of antibiotic use, with a 397% increase (2019: 0.45; 2020: 2.24 DHPD) in use. In summary, the pandemic had a major impact on the scale and pattern of hospital antibiotic use in Hungary. LA - English DB - MTMT ER -